Three Korean Firms Among Asia-Pacific’s 'Top 10 Biopharma Deals'

In a significant achievement for the South Korean biopharma sector, three companies have been recognized among the top 10 biopharma deals in the Asia-Pacific region for 2026.

Samsung BioLogics' acquisition of PolyPeptide Group secured the sixth position, highlighting its strategic move to enhance capabilities in peptide contract development and manufacturing. This deal comes amidst a growing global demand for treatments targeting obesity and diabetes.

SK Biopharmaceuticals followed closely, ranking seventh for its proactive acquisition of rights to the epilepsy drug candidate, Opacalim. The company made a notable upfront payment, securing U.S. assets even before the release of critical clinical results.

Hanmi Pharmaceutical's licensing agreement with Genentech, a Roche Group subsidiary, earned the ninth spot, with an impressive upfront payment of $190 million for a metabolic disease treatment candidate.

These achievements underscore the growing influence and innovation of Korean firms in the biopharmaceutical landscape, reflecting their commitment to advancing healthcare solutions.